Panduan Obat

109 artikel

Semua artikel
Panduan Obat

Oral Wegovy Side Effects: Nausea & Warnings (2026)

Oral Wegovy's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild-to-moderate and worst during dose increases. Because oral Wegovy is the same molecule as injectable Wegovy (semaglutide), it shares the *same* side-effect profile and the *same* serious warnings, including pancreatitis, gallbladder disease, and a boxed thyroid warning.

10 menit
Panduan Obat

Orforglipron Side Effects: Nausea, Warnings (2026)

Orforglipron's most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — which are dose-dependent, tend to be worst around each dose increase, and usually settle as the body adapts. Rare but serious risks include a boxed warning for thyroid C-cell tumors plus pancreatitis and gallbladder disease, which need urgent medical care.

8 menit
Panduan Obat

Retatrutide Side Effects: Trial Data & Warnings 2026

In clinical trials, retatrutide's most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — mostly mild-to-moderate and worst during dose escalation. Its triple-agonist design also produces two distinctive signals: abnormal skin sensations (dysesthesia) and a modest heart-rate increase. Retatrutide is investigational and available only through clinical trials — it cannot be prescribed.

7 menit
Panduan Obat

Semaglutide vs Tirzepatide: Which Is Right for You? (2026)

Tirzepatide (Mounjaro, Zepbound) acts on two hormones (GIP + GLP-1) and produced greater average weight loss in trials (~21%) than semaglutide (Ozempic, Wegovy, ~15%). But semaglutide has the longer track record and strong cardiovascular data. The "better" one depends on your goals, tolerance, cost, and prescriber.

4 menit
Panduan Obat

GLP-1 Side Effects: Ozempic, Wegovy & Tirzepatide Guide (2026)

The most common GLP-1 side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — and they are usually mild, most likely when starting or increasing the dose, and tend to ease within a few weeks. Rare but serious risks include pancreatitis, gallbladder problems, and severe delayed stomach emptying, which need urgent medical attention.

8 menit
Panduan Obat

How Much Does Wegovy & Ozempic Cost in 2026? Full Price Breakdown

Without insurance, Ozempic and Wegovy have list prices of roughly $970–$1,350 per month. But almost nobody pays that. Through the manufacturer's cash-pay pharmacy (NovoCare), self-pay prices in 2026 are about $349–$499/month for the injection and $149–$299/month for the newer oral pill — and with commercial insurance plus a savings card, eligible patients can pay as little as $0–$25 a month.

7 menit
Panduan Obat

Mounjaro Side Effects: Nausea, Sulfur Burps & Timeline (2026)

Mounjaro's most common side effects are gastrointestinal — nausea, diarrhea, decreased appetite, vomiting, and constipation — usually mild and worst during dose increases. Many users also report sulfur ("egg") burps. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.

9 menit
Panduan Obat

Ozempic Side Effects: Nausea, Timeline & Warnings (2026)

Ozempic's most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — usually mild and worst during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent care.

9 menit
Panduan Obat

Semaglutide Side Effects: Ozempic, Wegovy & Rybelsus (2026)

Semaglutide's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Frequency depends on the product and dose: highest with Wegovy 2.4 mg (weight loss), lower with Ozempic and oral Rybelsus (diabetes). Rare serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.

10 menit
Panduan Obat

Tirzepatide Side Effects: Mounjaro & Zepbound (2026)

The most common tirzepatide side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent medical care.

9 menit
Panduan Obat

Wegovy Side Effects: Nausea, Hair Loss & Timeline (2026)

Wegovy's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Because Wegovy titrates to a higher 2.4 mg dose, these are reported more often than with Ozempic. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.

10 menit
Panduan Obat

Zepbound Side Effects: Nausea, Hair Loss & Timeline (2026)

Zepbound's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Injection-site reactions and hair loss are also labeled. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent care.

11 menit
Panduan Obat

GLP-1 Saja Tidak Cukup — Model "Obat + Terapi Perilaku" yang Direkomendasikan WHO/ADA, dan Tahapan M0/M1/M2 HAVIT

Agonis reseptor GLP-1 (Wegovy, Mounjaro, Zepbound) menghasilkan penurunan berat badan rata-rata 15–22% (STEP 1, SURMOUNT-1). Namun STEP 4 melaporkan kenaikan kembali +11,6%p satu tahun setelah penghentian — sekitar 78% dari penurunan berat badan kembali. WHO (2022) dan ADA Standards (2024) secara eksplisit merekomendasikan terapi perilaku bersama farmakoterapi, dan STEP 3 (JAMA 2021) menunjukkan Terapi Perilaku Intensif dalam kombinasi mencapai hampir 3× penurunan berat badan dibanding kombinasi perawatan standar (−16% vs −5,7%). HAVIT menyusun ini dalam 3 tahap — pra-pengobatan (M0), adaptasi (M1), pemeliharaan/penghentian (M2) — mengintegrasikan obat, pelestarian otot, dan pembelajaran perilaku. HAVIT tidak meresepkan GLP-1; resep, dosis, dan penghentian tetap menjadi domain dokter.

14 menit

Siap Turun Berat Badan dengan Lebih Cerdas?

Semua yang Anda butuhkan untuk menurunkan berat badan, menjaga otot, dan membangun kebiasaan sehat — dalam satu aplikasi berbasis AI.

Download on the App StoreGet it on Google Play

Gratis diunduh. Mungkin ada pembelian dalam aplikasi.